Latest news
Expanded approval for Praluent in EU
European regulators have
approved a new indication for Regeneron and Sanofi’s Praluent (alirocumab) to
reduce cardiovascular risk in adults with established atherosclerotic CV
disease (ASCVD).
Roche’s MabThera approved in Europe for pemphigus vulgaris
Roche’s MabThera
(rituximab) has been approved in Europe for the treatment of adults with
moderate-to-severe pemphigus vulgaris (PV).
PV is a...
Iktos and Merck discovering new compounds with AI
A new collaboration
agreement will see Iktos use its generative modelling AI technology to
facilitate the rapid and cost-effective discovery and design of promising...
